GILD Stock Analysis: Gilead Sciences | NASDAQ
Drug Manufacturers - General | NASDAQ, USA | Market Cap: 177.859m USD | 12M Return: 31.9% | US3755581036 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 879M
Qual. Beats: 1
Rev. Trend: 97.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Gilead Sciences is a U.S.-headquartered biopharmaceutical company founded in 1987 and based in Foster City, California. Listed on NASDAQ since 1992, it operates in the biotechnology sub-industry of health care, discovering, developing, and commercializing medicines primarily in areas of unmet medical need across the United States, Europe, and other international markets.
The companys commercial portfolio spans several major therapeutic areas. Its HIV franchise includes Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, and Yeztugo for the treatment of HIV-1 infection. For liver diseases, Gilead markets Epclusa and Vemlidy (hepatitis B and C) and Livdelzi (primary biliary cholangitis). In oncology, it offers Tecartus and Yescarta as CAR T-cell therapies, along with Trodelvy for certain cancers. Additional products include AmBisome for serious invasive fungal infections and Veklury for COVID-19. Biopharmaceutical companies like Gilead typically generate revenue through prescription drug sales protected by patents and regulatory exclusivity periods.
Gilead supplements its internal pipeline with extensive external partnerships, holding collaboration or licensing agreements with entities including Arcus Biosciences, Merck Sharp & Dohme Corp., Janssen Sciences Ireland, Everest Medicines, Assembly Biosciences, Merus N.V., Terray Therapeutics, and LEO Pharma. These agreements cover areas such as trispecific antibodies, small molecule therapies, and the oral STAT6 program. Partnership-driven R&D is a common feature of the biotech sector, where licensing and collaboration deals help spread development risk and broaden pipeline access.
- Biktarvy patent expiry threatens core HIV franchise revenue
- Lenacapavir PrEP approval accelerates HIV growth runway
- Yescarta CAR-T sales pressured by bispecific antibody competition
| Net Income: -3.24b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 9.93 > 1.0 |
| NWC/Revenue: 9.60% < 20% (prev 12.23%; Δ -2.62% < -1%) |
| CFO/TA 0.27 > 3% & CFO 13.6b > Net Income -3.24b |
| Net Debt (23.1b) to EBITDA (1.37b): 16.80 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.24b) vs 12m ago -0.96% < -2% |
| Gross Margin: 79.59% > 18% (prev 78.53%; Δ 1.05% > 0.5%) |
| Asset Turnover: 57.97% > 50% (prev 51.80%; Δ 6.17% > 0%) |
| Interest Coverage Ratio: -1.39 > 6 (EBIT TTM -1.39b / Interest Expense TTM 998.0m) |
| A: 0.06 (Total Current Assets 13.9b - Total Current Liabilities 11.0b) / Total Assets 49.4b |
| B: 0.04 (Retained Earnings 2.20b / Total Assets 49.4b) |
| C: -0.03 (EBIT TTM -1.39b / Avg Total Assets 52.5b) |
| D: 0.31 (Book Value of Equity 11.8b / Total Liabilities 37.6b) |
| Altman-Z'' = 0.69 = B |
| DSRI: 1.00 (Receivables 5.05b/4.78b, Revenue 30.5b/28.9b) |
| GMI: 0.99 (GM 78.53% / 79.59%) |
| AQI: 0.94 (AQ_t 0.60 / AQ_t-1 0.64) |
| SGI: 1.06 (Revenue 30.5b / 28.9b) |
| TATA: -0.34 (NI -3.24b - CFO 13.6b) / TA 49.4b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of August 25, 2026, the stock is trading at USD 146.74 with a total of 6,181,558 shares traded. Over the past week, the price has changed by +5.63%, over one month by +13.48%, over three months by +10.45% and over the past year by +31.90%.
Current recommended Stop Loss: 141.30 (which is 3.7% or 1.3 ATR below the current price).
Gilead Sciences has received a consensus analysts rating of 4.13. Therefore, it is recommended to buy GILD.
- StrongBuy: 15
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 157.4 | 7.3% |
P/E Forward = 15.2207
P/S = 5.8397
P/B = 14.5633
P/EG = 2.1441
Revenue TTM = 30.5b USD
EBIT TTM = -1.39b USD
EBITDA TTM = 1.37b USD
Long Term Debt = 23.8b USD (from longTermDebt, last quarter)
Short Term Debt = 2.41b USD (from shortTermDebt, last quarter)
Debt = 26.2b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.1b USD (calculated: Debt 26.2b - CCE 3.18b)
Enterprise Value = 201b USD (178b + Debt 26.2b - CCE 3.18b)
Interest Coverage Ratio = -1.39 (Ebit TTM -1.39b / Interest Expense TTM 998.0m)
EV/FCF = 15.22x (Enterprise Value 201b / FCF TTM 13.2b)
FCF Yield = 6.57% (FCF TTM 13.2b / Enterprise Value 201b)
FCF Margin = 43.34% (FCF TTM 13.2b / Revenue TTM 30.5b)
Net Margin = -10.64% (Net Income TTM -3.24b / Revenue TTM 30.5b)
Gross Margin = 79.59% ((Revenue TTM 30.5b - Cost of Revenue TTM 6.22b) / Revenue TTM)
Gross Margin QoQ = 79.76% (prev 79.24%)
Tobins Q-Ratio = 4.07 (Enterprise Value 201b / Total Assets 49.4b)
Interest Expense / Debt = 3.80% (Interest Expense 998.0m / Debt 26.2b)
Taxrate = 13.13% (1.29b / 9.80b)
NOPAT = -1.20b (EBIT -1.39b * (1 - 13.13%)) [loss with tax shield]
Current Ratio = 1.27 (Total Current Assets 13.9b / Total Current Liabilities 11.0b)
Debt / Equity = 2.22 (Debt 26.2b / totalStockholderEquity, last quarter 11.8b)
Debt / EBITDA = 16.80 (Net Debt 23.1b / EBITDA 1.37b)
Debt / FCF = 1.75 (Net Debt 23.1b / FCF TTM 13.2b)
Total Stockholder Equity = 19.9b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.17% (Net Income -3.24b / Total Assets 49.4b)
RoE = -16.28% (Net Income TTM -3.24b / Total Stockholder Equity 19.9b)
RoCE = -3.17% (EBIT -1.39b / Capital Employed (Equity 19.9b + L.T.Debt 23.8b))
RoIC = -3.07% (negative operating profit) (NOPAT -1.20b / Invested Capital 39.2b)
WACC = 6.25% (E(178b)/V(204b) * Re(6.69%) + D(26.2b)/V(204b) * Rd(3.80%) * (1-Tc(0.13)))
Discount Rate = 6.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -14.51 | Cagr: -0.14%
[DCF] Terminal Value 77.97% ; FCFF base≈11.7b ; Y1≈13.4b ; Y5≈19.7b
[DCF] Fair Price = 220.3 (EV 296b - Net Debt 23.1b = Equity 273b / Shares 1.24b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.84 | # QB: 1
Revenue Correlation: 97.85 | Revenue CAGR: 3.95% | SUE: 1.82 | # QB: 1
EPS current Quarter (2026-09-30): EPS=2.15 | Chg30d=-3.38% | Revisions=-24% | Analysts=20
EPS current Year (2026-12-31): EPS=-0.43 | Chg30d=+43.77% | Revisions=+77% | GrowthEPS=-105.3% | GrowthRev=+4.3%
EPS next Year (2027-12-31): EPS=9.89 | Chg30d=+1.83% | Revisions=+59% | GrowthEPS=+2377.2% | GrowthRev=+6.5%
[Analyst] Revisions Ratio: +47% (up=39, down=13)